John H. Growdon
#112,968
Most Influential Person Now
John H. Growdon's AcademicInfluence.com Rankings
John H. Growdonphilosophy Degrees
Philosophy
#4797
World Rank
#7446
Historical Rank
Logic
#2182
World Rank
#3117
Historical Rank
John H. Growdonbiology Degrees
Biology
#6362
World Rank
#9059
Historical Rank
Neuroscience
#769
World Rank
#801
Historical Rank
Download Badge
Philosophy Biology
John H. Growdon's Degrees
- Doctorate Medicine Stanford University
Why Is John H. Growdon Influential?
(Suggest an Edit or Addition)John H. Growdon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease (1992) (2472)
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (2382)
- A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. (1997) (2355)
- Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) (1676)
- Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) (1656)
- Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease (1997) (1388)
- Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. (1993) (1186)
- Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
- Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. (1992) (915)
- Effect of deprenyl on the progression of disability in early Parkinson's disease. (1989) (886)
- The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals (2008) (877)
- A Neural Dissociation within Language: Evidence that the Mental Dictionary Is Part of Declarative Memory, and that Grammatical Rules Are Processed by the Procedural System (1997) (759)
- Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
- Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain (2004) (635)
- Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue (2015) (553)
- Monitoring Motor Fluctuations in Patients With Parkinson's Disease Using Wearable Sensors (2009) (548)
- Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
- Evidence for a membrane defect in Alzheimer disease brain. (1992) (518)
- Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
- Molecular markers of early Parkinson's disease based on gene expression in blood (2007) (462)
- Imaging amyloid deposition in Lewy body diseases (2008) (434)
- Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. (1993) (391)
- Effects of normal aging and Alzheimer's disease on emotional memory. (2002) (364)
- Semantic impairment and anomia in Alzheimer's disease (1986) (356)
- DLB and PDD boundary issues (2007) (351)
- Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. (2007) (349)
- Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. (2011) (348)
- Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease (1996) (329)
- Visual dysfunction in Alzheimer's disease: Relation to normal aging (1991) (324)
- Treatment for Alzheimer's disease? (1992) (320)
- Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy (2006) (311)
- Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis (2012) (308)
- Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study (1996) (288)
- White matter pathology isolates the hippocampal formation in Alzheimer's disease (2010) (278)
- Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease (2011) (274)
- Evidence for a dissociation between perceptual and conceptual priming in Alzheimer's disease. (1991) (274)
- Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. (1999) (255)
- Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels (2003) (247)
- Remote memory function in Alzheimer's disease and Parkinson's disease. (1988) (241)
- Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. (1995) (232)
- Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. (1993) (232)
- Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease (2008) (225)
- Serotonin 5-HT2a and 5-HT2c Receptors Stimulate Amyloid Precursor Protein Ectodomain Secretion (*) (1996) (222)
- Current pharmacotherapy for Alzheimer's disease. (2006) (211)
- Intact acquisition and long-term retention of mirror-tracing skill in Alzheimer's disease and in global amnesia. (1993) (208)
- Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. (2006) (199)
- Clinical and quantitative pathologic correlates of dementia with Lewy bodies (1999) (196)
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's (2016) (196)
- Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2019) (194)
- Temporal ordering and short-term memory deficits in Parkinson's disease. (1988) (192)
- Potential use of nerve growth factor to treat Alzheimer's disease (1989) (175)
- Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies (2017) (173)
- Dissociations Among Structural-Perceptual, Lexical-Semantic, and Event-Fact Memory Systems in Alzheimer, Amnesic, and Normal Subjects (1994) (170)
- Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease (1996) (167)
- Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. (2016) (167)
- Carbohydrate craving in obese people: Suppression by treatments affecting serotoninergic transmission (1981) (161)
- Spatial, but not object, delayed response is impaired in early Parkinson's disease. (1997) (158)
- Donepezil therapy in clinical practice: a randomized crossover study. (2000) (158)
- Clozapine and risperidone treatment of psychosis in Parkinson's disease. (2000) (156)
- Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. (2013) (156)
- Brain amyloid and cognition in Lewy body diseases (2012) (156)
- Oral choline administration to patients with tardive dyskinesia. (1977) (156)
- Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease (2005) (152)
- The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease (2000) (151)
- A recommended scale for cognitive screening in clinical trials of Parkinson's disease (2010) (150)
- Genetic association of an (α2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease (1998) (150)
- Visual dysfunction predicts cognitive deficits in Alzheimer's disease. (1995) (149)
- Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia (2013) (147)
- Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. (2010) (146)
- Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. (2003) (145)
- The effect of alcohol on essential tremor (1975) (144)
- Assessment of genetic risk for alzheimer's disease among first‐degree relatives (1989) (144)
- Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. (2014) (140)
- Spatial vision in Alzheimer's disease. General findings and a case report. (1985) (138)
- Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. (2006) (133)
- Working memory in mild Alzheimer's disease and early Parkinson's disease. (2003) (132)
- A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. (2013) (130)
- Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. (2000) (129)
- Age at Onset and Rate of Progression of Alzheimer's Disease (1987) (127)
- Prevalence of visual deficits in Alzheimer's disease. (1995) (126)
- LECITHIN CONSUMPTION RAISES SERUM-FREE-CHOLINE LEVELS (1977) (126)
- Mood, performance, and pain sensitivity: changes induced by food constituents. (1982) (124)
- Beta-adrenergic mechanisms in action tremor. (1975) (123)
- Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype (1995) (122)
- Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts (2017) (122)
- d-Fenfluramine selectively suppresses carbohydrate snacking by obese subjects. (1985) (119)
- Normal plasma choline responses to ingested lecithin (1980) (115)
- Elevation of cystatin C in susceptible neurons in Alzheimer's disease. (2001) (113)
- Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. (1994) (109)
- Haplotypes and gene expression implicate the MAPT region for Parkinson disease (2008) (108)
- Apolipoprotein E genotype in patients with alzheimer's disease: Implications for the risk of dementia among relatives (1995) (107)
- Incomplete achromatopsia in alzheimer's disease (1993) (106)
- Increased blood mercury levels in patients with Alzheimer's disease (1998) (106)
- Relations between dietary choline or lecithin intake, serum choline levels, and various metabolic indices. (1978) (105)
- Relation Between Clinical Characteristics of Parkinson's Disease and Cognitive Decline (2003) (103)
- The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study (2008) (102)
- Cognitive impairments in Parkinson's disease. (1987) (101)
- Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. (1995) (100)
- Transmission and age‐at‐onset patterns in familial Alzheimer's disease (1990) (100)
- Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients (1998) (99)
- Effects of Alzheimer disease on memory for verbal emotional information (2004) (97)
- Shorter Telomeres May Mark Early Risk of Dementia: Preliminary Analysis of 62 Participants from the Nurses' Health Study (2008) (96)
- Analysis of Feature Space for Monitoring Persons with Parkinson's Disease With Application to a Wireless Wearable Sensor System (2007) (94)
- Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. (2004) (94)
- Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. (2008) (93)
- Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease (1989) (92)
- Mild to moderate Alzheimer dementia with insufficient neuropathological changes (2014) (91)
- Retinocalcarine function in Alzheimer's disease. A clinical and electrophysiological study. (1992) (91)
- PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. (2002) (91)
- Segregation analysis reveals evidence of a major gene for Alzheimer disease. (1991) (91)
- Differences between Pick disease and Alzheimer disease in clinical appearance and rate of cognitive decline. (2000) (89)
- No Genetic Effect of α1-Antichymotrypsin in Alzheimer Disease (1996) (88)
- Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. (1982) (87)
- Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity (1998) (87)
- Portable system for quantifying motor abnormalities in Parkinson's disease (1993) (86)
- Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients (1990) (86)
- 5-hydroxytryptophan-induced myoclonus: Increased sensitivity to serotonin after intracranial 5,7-dihydroxytryptamine in the adult rat (1976) (82)
- Selective attention in Alzheimer's disease: Characterizing cognitive subgroups of patients (1989) (82)
- Single photon emission computed tomography in Alzheimer's disease. Abnormal iofetamine I 123 uptake reflects dementia severity. (1988) (80)
- Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease (1994) (80)
- In Vitro31P NMR Spectroscopy Detects Altered Phospholipid Metabolism in Alzheimer's Disease (1986) (78)
- A novel presenilin‐1 mutation: Increased β‐amyloid and neurofibrillary changes (1997) (77)
- Linkage of late-onset Alzheimer's disease with apolipoprotein E type 4 on chromosome 19 (1993) (76)
- Auditory function in Alzheimer's disease (1993) (76)
- Lecithin can suppress tardive dyskinesia. (1978) (75)
- Comparison of magnetic resonance and roentgen ray computed tomography in dementia. (1987) (75)
- Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. (1990) (73)
- Priming in perceptual identification of pseudowords is normal in Alzheimer's disease (1994) (73)
- TAR-DNA Binding Protein 43 in Pick Disease (2008) (73)
- The effects of dietary neurotransmitter precursors on human behavior. (1985) (73)
- CELL MEMBRANE ABNORMALITY IN ALZHEIMER'S DISEASE (1984) (72)
- Presenilin 1 Protein Directly Interacts with Bcl-2* (1999) (72)
- Huntington's disease: Clinical and chemical effects of choline administration (1977) (71)
- Epidemiological, Clinical, and Neuropathological Study of Apolipoprotein E Genotype in Alzheimer's Disease (1996) (69)
- Idazoxan treatment in progressive supranuclear palsy (1991) (68)
- CSF somatostatin‐like immunoreactivity in dementia (1986) (68)
- Broad-band visual capacities are not selectively impaired in Alzheimer's disease (1994) (67)
- Differential effects of DSP-4 administration on regional brain norepinephrine turnover in rats. (1985) (66)
- The time course of spatial and object learning in Parkinson's disease (1997) (66)
- Structure and Functions of Human Cerebrospinal Fluid Lipoproteins from Individuals of Different APOE Genotypes (1998) (65)
- An experimental study of cerebellar dyskinesia in the rhesus monkey. (1967) (65)
- Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. (1996) (65)
- Effects of oral choline administration on serum and CSF choline levels in patients with Huntington's Disease 1 (1977) (65)
- Unrecognized vitamin D3 deficiency is common in Parkinson disease (2013) (64)
- Impaired problem solving in Parkinson's disease: Impact of a set-shifting deficit (1994) (63)
- Visual Function in Alzheimer's Disease and Normal Aging a (1991) (62)
- Different cognitive profiles on standard behavioral tests in Parkinson's disease and Alzheimer's disease. (1989) (62)
- Pattern of recovery following cerebellar deep nuclear lesions in monkeys. (1973) (62)
- Greater Relative Impairment of Object Recognition Than of Visuospatial Abilities in Alzheimer's Disease (1996) (62)
- Elevation of plasma tyrosine after a single oral dose of L-tyrosine. (1979) (62)
- Biomarkers of Alzheimer disease. (1999) (62)
- Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease (2007) (61)
- The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease (1994) (61)
- Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. (2013) (60)
- Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. (2015) (60)
- Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. (1979) (60)
- Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers (2010) (59)
- A haplotype at the PARK3 locus influences onset age for Parkinson’s disease (2003) (58)
- Arguing against the proposed definition changes of PD (2016) (58)
- Epidemiologic study of 203 sibling pairs with Parkinson’s disease (2002) (57)
- Sensory symptoms in cranial dystonia: A potential role in the etiology? (1993) (57)
- Sharpen that needle. (2010) (56)
- Is Alzheimer's Disease Risk Modifiable? (2019) (56)
- Distinctive aspects of cognitive dysfunction in Parkinson's disease. (1990) (56)
- Transmission and age-at-onset patterns in familial Alzheimer??s disease: evidence for heterogeneity (1991) (56)
- Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's Disease (2000) (55)
- Dissociations Among Processes in Remote Memory (1985) (55)
- Oral dyskinesia in rats following brain lesions and neuroleptic drug administration (2004) (54)
- Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. (1996) (54)
- L‐5‐hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent (1976) (53)
- BMC Medicine (2006) (53)
- Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study (2003) (52)
- Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies (2006) (52)
- Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. (2010) (52)
- Genome-wide scan for Parkinson's disease: the GenePD Study. (2001) (51)
- Myoclonus after 5‐hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system (1976) (50)
- Tyrosine for the treatment of depression. (1980) (49)
- Piracetam combined with lecithin in the treatment of Alzheimer's disease (1986) (49)
- Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease (2021) (49)
- Alterations of Phospholipid Metabolites in Postmortem Brain from Patients with Alzheimer's Disease a (1991) (48)
- Increase in hippocampal acetylcholine after choline administration (1977) (48)
- Cerebral perfusion in progressive supranuclear palsy. (1992) (48)
- Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease (2012) (47)
- Midbrain ptosis. A case with clinicopathologic correlation. (1974) (47)
- Environment-driven responses in progressive supranuclear palsy (1995) (47)
- Genome-wide scan for Parkinson's disease (2001) (47)
- Cholinesterases in cerebrospinal fluid Correlations with clinical measures in Alzheimer's disease (1986) (46)
- Weight Loss in Alzheimer's Disease (1993) (46)
- A balanced carbohydrate (1991) (45)
- No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer’s disease brain (2006) (45)
- Verbal and nonverbal short‐term memory in patients with Alzheimer's disease and in healthy elderly subjects (1986) (45)
- CSF vasopressin concentration is reduced in Alzheimer's disease (1986) (45)
- Interrater agreement for diagnosis of Alzheimer's disease (1994) (44)
- Multiple etiologies for Alzheimer disease are revealed by segregation analysis. (1994) (43)
- Association of decreased paternal age and late-onset Alzheimer's disease. An example of genetic imprinting? (1991) (43)
- Unraveling the Mystery of Cognitive Changes in Old Age: Correlation of Neuropsychological Evaluation With Neuropathological Findings in the Extreme Old (1998) (43)
- PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies (2015) (43)
- Choline metabolism in cholinergic neurons: implications for the pathogenesis of neurodegenerative diseases. (1990) (43)
- Receptor‐coupled Amyloid Precursor Protein Processing a (1993) (42)
- Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. (1998) (42)
- Parental age as a risk factor in Alzheimer's disease (1983) (42)
- Replication of association between ELAVL4 and Parkinson disease: the GenePD study (2008) (41)
- Neurological Abnormalities Associated with Severity of Dementia in Alzheimer's Disease (1986) (41)
- Presenilin-1 polymorphism and Alzheimer's disease (1996) (39)
- Postural changes, tremor, and myoclonus in the rat immediately following injections of p‐chloroamphetamine (1977) (39)
- Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age (2006) (39)
- Lecithin does not affect EEG spectral analysis or P300in Alzheimer disease (1982) (39)
- Rarity of the Alzheimer disease-protective APP A673T variant in the United States. (2015) (39)
- Dietary influences on the synthesis of neurotransmitters in the brain. (2009) (37)
- Category knowledge in Alzheimer's disease: normal organization and a general retrieval deficit. (1992) (37)
- Vasopressin and Bradykinin Regulate Secretory Processing of the Amyloid Protein Precursor of Alzheimer's Disease (1998) (36)
- Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains (2007) (36)
- An antispasticity effect of threonine in multiple sclerosis. (1992) (34)
- Intact implicit memory for novel patterns in Alzheimer's disease. (1996) (34)
- Metabotropic glutamate receptor subtype mGluR1alpha stimulates the secretion of the amyloid beta-protein precursor ectodomain. (1997) (34)
- Muscarinic agonists in Alzheimer's disease. (1997) (34)
- CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease. (1985) (34)
- Biomarkers and surrogates (2004) (34)
- Electrophysiologic detection of extrapyramidal motor signs in Alzheimer's disease (1993) (33)
- Rate of progression of Alzheimer's disease is associated with genetic risk. (1995) (33)
- Regulation of proteolytic processing of the amyloid beta-protein precursor of Alzheimer's disease in transfected cell lines and in brain slices. (1994) (32)
- Pupil dilation to tropicamide is not specific for Alzheimer disease. (1997) (32)
- Quantitative In Vivo 31P Magnetic Resonance Spectroscopy of Alzheimer Disease (1996) (32)
- Incorporating biomarkers into clinical drug trials in Alzheimer's disease. (2001) (32)
- Treatment of brain disease with dietary precursors of neurotransmitters. (1977) (31)
- Prevalence and Effects of Lobar Microhemorrhages in Early-Stage Dementia (2006) (30)
- Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. (2006) (30)
- Using wearable sensors to predict the severity of symptoms and motor complications in late stage Parkinson's Disease (2008) (30)
- Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier (2004) (30)
- Regulation of APP Processing Potential for the Therapeutical Reduction of Brain Amyloid Burden a (1996) (30)
- Assessing treatment effects: A neuropsychological battery. (1986) (30)
- Perceptual organization in Alzheimer's disease. (1994) (29)
- Choline and lecithin in brain disorders (1979) (29)
- Risperidone treatment of behavioral disturbances in outpatients with dementia. (1999) (28)
- Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study (2014) (28)
- L‐Threonine in the Treatment of Spasticity (1991) (27)
- Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study (2011) (26)
- Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
- Cognitive functions affected by scopolamine in alzheimer's disease and normal aging (1988) (26)
- Levodopa Induction of Fos Immunoreactivity in Rat Brain Following Partial and Complete Lesions of the Substantia Nigra (1993) (25)
- Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments (1988) (24)
- CLINICAL FEATURES OF ALZHEIMER??S DISEASE (1992) (24)
- A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. (1998) (22)
- Potential use of nerve growth factor to treat Alzheimer's disease. (1989) (21)
- Putamen–midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases (2015) (21)
- Regulation of proteolytic processing of the amyloid beta-protein precursor by first messengers. A novel potential approach for the treatment of Alzheimer's disease. (1995) (20)
- CHANGES IN MOTOR BEHAVIOR FOLLOWING THE ADMINISTRATION OF SEROTONIN NEUROTOXINS * (1978) (20)
- Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. (2020) (20)
- Accelerometer data collected with a minimum set of wearable sensors from subjects with Parkinson’s disease (2021) (20)
- Physical properties of the lungs in giant cysts. Report of a case treated surgically. (1962) (20)
- Apolipoprotein E and Alzheimer disease. (1998) (19)
- No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. (1996) (18)
- Pattern of Depressive Symptoms in Parkinson's Disease (2009) (17)
- Effects of proximal and distal muscles' groups contraction and mental stress on the amplitude and frequency of physiological finger tremor. An accelerometric study. (2000) (17)
- Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease (2019) (17)
- Phospholipid metabolite levels are altered in cerebral cortex of patients with dominantly inherited olivopontocerebellar atrophy (1993) (16)
- Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ‐1 (T497C) genes in familial Parkinson's disease from the GenePD study (2005) (16)
- Dr. Gelenberg and Associates Reply (1979) (16)
- Rationale and Design of a Multicenter Study of Selegiline and α-Tocopherol in the Treatment of Alzheimer Disease Using Novel Clinical Outcomes (1996) (16)
- Correlational analysis of five commonly used measures of mental status/functional abilities in patients with Alzheimer disease. (1999) (15)
- The effects of tryptophan and tyrosine on human mood and performance. (1984) (15)
- Assessing depression and factors possibly associated with depression during the course of Parkinson's disease. (2011) (14)
- CSF neurotransmitter markers in Alzheimer's disease (1986) (14)
- Apolipoprotein E ϵ4/4 in a Neuropathologically Normal Very Elderly Individual (1996) (13)
- Abstract reasoning in age-related neurological disease. (1987) (12)
- Dietary enhancement of CNS neurotransmitters. (1978) (12)
- β-Glucocerebrosidase Activity in GBA-linked Parkinson's Disease: The Type of Mutation Matters. (2020) (12)
- Neurochemical approaches to the treatment of senile dementia. (1980) (11)
- Clinical Evaluation of Compounds for the Treatment of Memory Dysfunction (1985) (11)
- No Association between α1‐Antichymotrypsin and Familial Alzheimer's Diseases a (1996) (11)
- Alzheimer's disease : amyloid precursor proteins, signal transduction, and neuronal transplantation (1993) (11)
- ALPHA SYNUCLEIN IMMUNOREACTIVITY IN DEMENTIA WITH LEWY BODIES (1999) (10)
- A Model for Oral Dyskinesia in Rats (1982) (10)
- 18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. (2020) (10)
- Topography of cortical thinning in the Lewy body diseases (2020) (10)
- The Dementias 2 (2007) (10)
- Pattern of depressive symptoms in Parkinson's disease. (2009) (10)
- Plasma tyrosine in normal humans: Effects of oral tyrosine and protein-containing meals (2005) (9)
- Novel Progranulin Mutation Detected in 2 Patients With FTLD (2011) (9)
- Therapy for progressive supranuclear palsy: past and future. (1994) (9)
- To tap or not to tap: Cerebrospinal fluid biomarkers of Alzheimer's disease (1998) (9)
- No Evidence of PGRN or MAPT Gene Dosage Alterations in a Collection of Patients with Frontotemporal Lobar Degeneration (2009) (9)
- Processing Wearable Sensor Data to Optimize Deep-Brain Stimulation (2008) (9)
- Aging and Alzheimer's Disease: Sensory Systems, Neuronal Growth, and Neuronal Metabolism (1991) (9)
- Limb and trunk accelerometer data collected with wearable sensors from subjects with Parkinson’s disease (2021) (9)
- Diagnosing dementia with Lewy bodies. (2002) (9)
- Serotonergic mechanisms in myoclonus. (1979) (8)
- Apolipoprotein E epsilon4/4 in a neuropathologically normal very elderly individual. (1996) (8)
- EVALUATION OF NIA-REAGAN INSTITUTE CRITERIA FOR THE NEUROPATHOLOGICAL DIAGNOSIS OF ALZHEIMER DISEASE (1997) (7)
- Massachusetts Alzheimer's Disease Research Center: Progress and challenges (2015) (7)
- Choline and lecithin administration to patients with tardive dyskinesia. (1978) (7)
- Use of Phosphatidylcholine in Brain Diseases: An Overview (1987) (7)
- Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study (2008) (7)
- The Neurobiology of Alzheimer's Disease (1996) (7)
- False-negative results with levodopa for early detection of Huntington's disease. (1982) (7)
- β-Glucocerebrosidase activity in GBA-linked Parkinson disease (2020) (7)
- Nutrients and neurotransmitters. (1980) (7)
- Topics in the basic and clinical science of dementia. Proceedings of the fourth Zürich meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. January 16-18, 1987. (1987) (6)
- Use of choline and lecithin in the treatment of tardive dyskinesia. (1980) (6)
- The differential diagnosis of tremor in Parkinson's disease. (1975) (6)
- Dietary Control of Central Cholinergic Activity (1979) (6)
- Genome-wide scan for Parkinson’s disease:: The Gene PD Study (2001) (6)
- Neuropharmacology of degenerative diseases associated with aging (1983) (5)
- Effects of choline on tardive dyskinesia and other movement disorders. (1978) (5)
- Apolipoprotein E epsilon2 does not increase risk of early-onset sporadic Alzheimer's disease. (1997) (5)
- APOE genotype and brain development. (2014) (5)
- Plasma choline responses to lecithin-enriched soup. (1984) (5)
- L-Threonine Administration Increases CSF Glycine Levels and Suppresses Spasticity (1987) (5)
- Reply: Beyond the limits of detection: Failure of PiB imaging to capture true Aβ burden (2013) (5)
- Molecular Genetic Strategies in Familial Alzheimer’s Disease: Theoretical and Practical Considerations (1988) (4)
- Can the immune system fight Alzheimer disease? (2006) (4)
- Effects of smoking and alcohol on Alzheimer disease: The mirage study (2000) (4)
- Comparison of rates of progression in Alzheimer's disease and Parkinson's disease. (1987) (4)
- Cholinergic neurones and memory (1981) (4)
- CHOLINE ADMINISTRATION TO PATIENTS WITH HUNTINGTON'S DISEASE OR TARDIVE DYSKINESIA (1979) (4)
- Aging, memory loss, and dementia. (1982) (4)
- Risk of alzheimer disease is associated with parental age among apolipoprotein E ε4 heterozygotes (1997) (4)
- Regulation of APP Processing by First Messengers (1994) (4)
- The molecular basis of dementia (2000) (4)
- Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90 (2022) (4)
- SECRETION OF ALZHEIMER AMYLOID PRECURSOR PROTEIN IS STIMULATED BY MUSCARINIC RECEPTOR ACTIVATION. (1992) (3)
- Exploring the use of wearable sensors to monitor drug response of patients with Parkinson’s disease in the home setting (P4.002) (2017) (3)
- No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. (1996) (3)
- Amino Acid Therapy in Neurological Disease (1988) (3)
- l-Tryptophan administration potentiates serotonin-dependent myoclonic behavior in the rat (1980) (3)
- Tau PET imaging in the Lewy body diseases (2017) (3)
- Choline Metabolism, Membrane Phospholipids, and Alzheimer’s Disease (1994) (3)
- Striatal and Extrastriatal Dopamine Transporter Levels Relate to Cognition in Lewy Body Diseases (P2.009) (2014) (3)
- The effects of cholinergic agonists on apomorphine-induced stereotyped behavior in the rat. (1978) (3)
- Challenges and opportunities in linking brain-based biomarkers to person-specific variation in cognition: pumping up the volume. (2015) (3)
- Deterioration on the blessed information-memory-concentration test in Alzheimer's disease (1992) (3)
- Biomarkers for Alzheimer’s Disease and Parkinson’s Disease (2008) (2)
- Phosphatidylcholine and tardive dyskinesia (1986) (2)
- DISTINCTIVE CORTICAL NEURONAL DEGENERATION IN PROGRESSIVE SUPRANUCLEAR PALSY (1993) (2)
- Treating Tardive Dyskinesia (1982) (2)
- The second meeting of the international study group on the pharmacology of memory disorders associated with aging (ISG) (1982) (2)
- Modulation of Presenilin‐1 Processing by Nitric Oxide during Apoptosis Induced by Serum Withdrawal and Glucose Deprivation (1999) (2)
- Beta-adrenergic mechanisms in essential tremor. (1974) (2)
- Plasma beta-amyloid linked to cognitive decline. (2011) (2)
- Diagnostic Methods in Alzheimer’s Disease: Magnetic Resonance Brain Imaging and CSF Neurotransmitter Markers (1986) (2)
- Commentary on “Diagnosis of Alzheimer’s disease: Two decades of progress.” The NIA’s Alzheimer Disease Centers (2005) (1)
- Amino acids as chemical transmitters. Edited by Frode Fonnum, 738 pages, Plenum Press, New York, NY, 1578. $49.50 (1980) (1)
- J. Stephen Fink, MD, PhD (1950–2002) (2003) (1)
- NEURONAL LOSS IN ALZHEIMERʼS DISEASE: RELATION TO TANGLES, PLAQUES, AND APOLIPOPROTEIN E (1996) (1)
- Estimation of familial risk in Alzheimer's disease (1990) (1)
- CNS biomarkers for Alzheimer's disease (2000) (1)
- The Search for Additional Alzheimer’s Disease Genes (1996) (1)
- Perceptual organization in Alzhiemer's disease. (1994) (1)
- Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altropane positron emission tomography study (2014) (1)
- The Human Alzheimer Disease Project: Answering the Call. (2016) (1)
- Idazoxan improves motor fnctiosn in Progressiev Supranuclear palsy (1991) (1)
- How to solve three puzzles. (2008) (1)
- Abnormal Phospholipid Metabolism in Neurodegenerative Diseases: Elevations in Glycerophosphocholine and Glycerophospho-Ethanolamine Levels in Brain of Alzheimer’s Disease But Not in Down Syndrome Patients (1990) (1)
- Reply to Tzourio et al. (1992) (1)
- Tau missing from CSF (2007) (1)
- Identification of a novel deletion in the splice donor site of progranulin exon 6 (2009) (1)
- Choline levels, the regulation of acetylcholine and phosphatidylcholine synthesis, and Alzheimer's disease (1989) (1)
- Biomarkers 101 (2005) (0)
- Acetylcholine in AD: Expectations meet reality (2006) (0)
- CerebralPerfusionin ProgressiveSupranuclear Palsy (1992) (0)
- Alzheimer’s disease: a disorder of the precortical visual system? (1986) (0)
- Reply to Borrie, Crilly, and Bowring (1987) (0)
- Meeting Report (1972) (0)
- Early diagnosis of Alzheimer's disease and related dementia (DIADEM) - A research network funded by the European Union (2002) (0)
- Modulation of APP Processing by Neurotransmission (1995) (0)
- The Role of Neurofilament Genes in Familial Alzheimer's Disease (1987) (0)
- Functional interaction between PS1 FAD mutants and Bcl-2 effects on mitochondrial events (2000) (0)
- DIADEM / Participants Directory (2004) (0)
- Limb and trunk accelerometer data collected with wearable sensors from subjects with Parkinson’s disease (2021) (0)
- Food and the Brain (1980) (0)
- Preface (2004) (0)
- disease without dementia Amyloid is linked to cognitive decline in patients with Parkinson (0)
- Dementia in Younger People: A Different Ballgame (2003) (0)
- Contents Vol. 4, 2007 (2007) (0)
- Oral Choline Adlninistration to Patients with Huntington ' s Disease * (2006) (0)
- Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
- Preface (1991) (0)
- Effects of Choline-Containing Compounds on Tardive Dyskinesia and Other Movement Disorders (1980) (0)
- Multiple system collagen disease: a new approach to its diagnosis. (1966) (0)
- Repression of presenilin 2 expression by oxidative stress (2000) (0)
- Accelerometer data collected with a minimum set of wearable sensors from subjects with Parkinson’s disease (2021) (0)
- Neuroanatomical correlates of semantic memory impairment seen in normal aging and early Alzheimer's disease, as measured by functional MRI (2001) (0)
- 191 Muscarinic agonists effects on APP processing — A potential causal treatment strategy in Alzheimer's disease (1996) (0)
- How Accurate Is the Clinical Diagnosis of Dementia (2003) (0)
- Subject Index Vol. 2, 2005 (2006) (0)
- Subject Index Vol. 4, 2007 (2007) (0)
- Accelerated Cell Membrane Degradation in Alzheimer’s Disease Brain: Relationship to Amyloid Formation? (1993) (0)
- Preface (1993) (0)
- AN ANIMAL MODEL OF PHARMACOLOGICAL THERAPY FOR TARDIVE DYSKINESIA USING CHOLINERGIC DRUGS (1979) (0)
- Biomarkers and surrogates (2004) (0)
- Toward a phenome-wide view of Parkinson's disease (2022) (0)
- IMP-SPECT Imaging in Alzheimer's Disease: Relationship to Dementia (1987) (0)
- Reply (1990) (0)
- Contents Vol. 2, 2005 (2006) (0)
- Comprar The Dementias 2 | John H. Growdon | 9780750675420 | Butterworth Heinemann (2007) (0)
- Aging and Alzheimer's disease (1991) (0)
- Diadem : Reports on early diagnosis of alzheimer's disease and related dementias (2004) (0)
- P2.213 Ab amyloid deposits are common in brains of non-demented PD patients (2009) (0)
- In Vitro 31 P NMR Spectroscopy Detects Altered Phospholipid Metabolism in Alzheimer ' s Disease (2015) (0)
- 22 Regulation of APP processing by muscarinic acetylcholine receptors in Alzheimer's disease patients (1996) (0)
- Reply (1990) (0)
- A New Direction for Treating Alzheimer Disease (2006) (0)
- Preface (2000) (0)
- Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer ' s disease [ Articles (2006) (0)
- Brain Phospholipids and their Metabolites in Alzheimer’s Disease: Possible Role of “Auto-Cannibalism” and Implications for Drug Development (1991) (0)
- 24. A novel approach to study the regulated release of secretory proteins from brain slices (1994) (0)
- Tau missing from CSF: a case report. (2007) (0)
- Reply (1996) (0)
- Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) (0)
- Contents Vol.19, 2019 (2020) (0)
- P3-229 Analysis of gene expression in the Alzheimer's disease brain (2004) (0)
- Evaluating CNS Biomarkers for Alzheimer's Disease (2002) (0)
- Lexical Memory is Part of the Temporal Lobe Declarative Memory , and that Grammatical Rules are Processed by the Frontal / Basal-Ganglia Procedural Memory System (2003) (0)
- Contrast sensitivity In Alzheimer's disease (1987) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John H. Growdon?
John H. Growdon is affiliated with the following schools:
